MedTrace Logo

Study of IMC-11F8 in Participants With Advanced Solid Tumors

NCT01088464 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2017-02-03

Study results available
· View outcomes & findings →

Summary

This study is to establish the safety and pharmacokinetic (PK) profile of IMC-11F8, administered either: (1) in a 3-week cycle; or (2) in a 2-week cycle to Japanese participants with advanced solid tumors who have not responded to standard therapy or for whom no standard therapy is available.

Conditions

  • Neoplasms

Interventions

BIOLOGICAL

IMC-11F8

600 milligrams (mg) intravenously, Days 1 and 8 every 3 weeks

BIOLOGICAL

IMC-11F8

800 mg intravenously, every 2 weeks

BIOLOGICAL

IMC-11F8

800 mg intravenously, Days 1 and 8 every 3 weeks

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01088464 on ClinicalTrials.gov